Shopping Cart 0
Cart Subtotal
USD 0

ContraFect Corp (CFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

ContraFect Corp (ContraFect) is a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. The company develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious diseases. Its lead product candidates include CF-301, a recombinant bacteriophage derived lysin intended for the treatment of staphylococcus aureus bloodstream infections and offers CF-404, a combination of human monoclonal antibodies intended for the treatment of seasonal and pandemic influenza infections. The company's pipeline portfolio consists other lysin candidates in preclinical stage. ContraFect is headquartered in Yonkers, New York, the US.

ContraFect Corp (CFRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraFect Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ContraFect Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ContraFect Corp, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

ContraFect Raises USD 12 Million In Venture Financing 11

ContraFect Raises USD 9.5 Million In Venture Financing 12

Partnerships 13

ContraFect Enters into Research Agreement with Rockefeller University 13

ContraFect Enters into Research Agreement with National Institute for Viral Disease Control and Prevention for CF-404 14

Licensing Agreements 15

ContraFect Enters Into Licensing Agreement With Trellis 15

ContraFect Amends Licensing Agreement With Trellis 16

Equity Offering 17

ContraFect Prices Public Offering of Shares for USD10 Million 17

ContraFect Raises USD40 Million in Public Offering of Shares and Warrants 19

ContraFect to Raise Up to USD4.9 Million in Public Offering of Shares 21

ContraFect Raises Funds through Public Offering of Shares and Warrants 22

ContraFect Raises USD35 Million in Public Offering of Shares 23

ContraFect Raises USD20 Million in Private Placement Shares and Warrants 24

ContraFect Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD41 Million 25

ContraFect Corp-Key Competitors 27

ContraFect Corp-Key Employees 28

ContraFect Corp-Locations And Subsidiaries 29

Head Office 29

Recent Developments 30

Financial Announcements 30

Aug 09, 2018: Contrafect announces second quarter 2018 financial results 30

May 10, 2018: ContraFect Announces First Quarter 2018 Financial Results 31

Mar 15, 2018: ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 32

Nov 09, 2017: ContraFect Announces Third Quarter 2017 Financial Results 34

Aug 09, 2017: ContraFect Announces Second Quarter 2017 Financial Results 35

May 08, 2017: ContraFect Announces First Quarter 2017 Financial Results 36

Mar 15, 2017: ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 37

Corporate Communications 39

Oct 05, 2017: ContraFect Appoints Lisa Ricciardi as Chief Operating Officer 39

Feb 15, 2017: Lisa Ricciardi to Join Board of Directors 40

Product News 41

11/15/2017: ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference 41

11/10/2017: ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference 42

10/17/2017: ContraFect to Present at the 4th Annual Re-entering Antibacterial Discovery and Development Summit 43

09/29/2017: ContraFect to Present New Data on CF-301 at ID Week 2017 44

09/11/2017: ContraFect to Present at 2017 World Antimicrobial Resistance Congress 45

04/11/2018: ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases 46

03/30/2017: ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program 48

Clinical Trials 49

Mar 14, 2018: ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference 49

Jan 03, 2018: ContraFect to Present at 10th Annual Biotech Showcase 50

Sep 28, 2017: ContraFect to Present at The MicroCap Conference 51

Sep 13, 2017: ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference 52

Jun 01, 2017: ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017 53

May 25, 2017: ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia 54

Apr 19, 2017: ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease 55

Jan 06, 2017: ContraFect Provides Update On Its Clinical Development Timeline For CF-301 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

ContraFect Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraFect Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ContraFect Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraFect Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraFect Corp, Deals By Therapy Area, 2012 to YTD 2018 9

ContraFect Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ContraFect Raises USD 12 Million In Venture Financing 11

ContraFect Raises USD 9.5 Million In Venture Financing 12

ContraFect Enters into Research Agreement with Rockefeller University 13

ContraFect Enters into Research Agreement with National Institute for Viral Disease Control and Prevention for CF-404 14

ContraFect Enters Into Licensing Agreement With Trellis 15

ContraFect Amends Licensing Agreement With Trellis 16

ContraFect Prices Public Offering of Shares for USD10 Million 17

ContraFect Raises USD40 Million in Public Offering of Shares and Warrants 19

ContraFect to Raise Up to USD4.9 Million in Public Offering of Shares 21

ContraFect Raises Funds through Public Offering of Shares and Warrants 22

ContraFect Raises USD35 Million in Public Offering of Shares 23

ContraFect Raises USD20 Million in Private Placement Shares and Warrants 24

ContraFect Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD41 Million 25

ContraFect Corp, Key Competitors 27

ContraFect Corp, Key Employees 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ContraFect Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ContraFect Corp (ContraFect) is a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. The company develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious diseases. Its lead product candidates include CF-301, a recombinant bacteriophage derived lysin intended for the treatment of staphylococcus aureus bloodstream infections and offers CF-404, a combination of human monoclonal antibodies intended for the treatment of seasonal and pandemic influenza infections. The company's pipeline portfolio consists other lysin candidates in preclinical stage. ContraFect is headquartered in Yonkers, New York, the US.

ContraFect Corp (CFRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraFect Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ContraFect Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ContraFect Corp, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

ContraFect Raises USD 12 Million In Venture Financing 11

ContraFect Raises USD 9.5 Million In Venture Financing 12

Partnerships 13

ContraFect Enters into Research Agreement with Rockefeller University 13

ContraFect Enters into Research Agreement with National Institute for Viral Disease Control and Prevention for CF-404 14

Licensing Agreements 15

ContraFect Enters Into Licensing Agreement With Trellis 15

ContraFect Amends Licensing Agreement With Trellis 16

Equity Offering 17

ContraFect Prices Public Offering of Shares for USD10 Million 17

ContraFect Raises USD40 Million in Public Offering of Shares and Warrants 19

ContraFect to Raise Up to USD4.9 Million in Public Offering of Shares 21

ContraFect Raises Funds through Public Offering of Shares and Warrants 22

ContraFect Raises USD35 Million in Public Offering of Shares 23

ContraFect Raises USD20 Million in Private Placement Shares and Warrants 24

ContraFect Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD41 Million 25

ContraFect Corp-Key Competitors 27

ContraFect Corp-Key Employees 28

ContraFect Corp-Locations And Subsidiaries 29

Head Office 29

Recent Developments 30

Financial Announcements 30

Aug 09, 2018: Contrafect announces second quarter 2018 financial results 30

May 10, 2018: ContraFect Announces First Quarter 2018 Financial Results 31

Mar 15, 2018: ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 32

Nov 09, 2017: ContraFect Announces Third Quarter 2017 Financial Results 34

Aug 09, 2017: ContraFect Announces Second Quarter 2017 Financial Results 35

May 08, 2017: ContraFect Announces First Quarter 2017 Financial Results 36

Mar 15, 2017: ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 37

Corporate Communications 39

Oct 05, 2017: ContraFect Appoints Lisa Ricciardi as Chief Operating Officer 39

Feb 15, 2017: Lisa Ricciardi to Join Board of Directors 40

Product News 41

11/15/2017: ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference 41

11/10/2017: ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference 42

10/17/2017: ContraFect to Present at the 4th Annual Re-entering Antibacterial Discovery and Development Summit 43

09/29/2017: ContraFect to Present New Data on CF-301 at ID Week 2017 44

09/11/2017: ContraFect to Present at 2017 World Antimicrobial Resistance Congress 45

04/11/2018: ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases 46

03/30/2017: ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program 48

Clinical Trials 49

Mar 14, 2018: ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference 49

Jan 03, 2018: ContraFect to Present at 10th Annual Biotech Showcase 50

Sep 28, 2017: ContraFect to Present at The MicroCap Conference 51

Sep 13, 2017: ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference 52

Jun 01, 2017: ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017 53

May 25, 2017: ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia 54

Apr 19, 2017: ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease 55

Jan 06, 2017: ContraFect Provides Update On Its Clinical Development Timeline For CF-301 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

ContraFect Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraFect Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ContraFect Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ContraFect Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ContraFect Corp, Deals By Therapy Area, 2012 to YTD 2018 9

ContraFect Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ContraFect Raises USD 12 Million In Venture Financing 11

ContraFect Raises USD 9.5 Million In Venture Financing 12

ContraFect Enters into Research Agreement with Rockefeller University 13

ContraFect Enters into Research Agreement with National Institute for Viral Disease Control and Prevention for CF-404 14

ContraFect Enters Into Licensing Agreement With Trellis 15

ContraFect Amends Licensing Agreement With Trellis 16

ContraFect Prices Public Offering of Shares for USD10 Million 17

ContraFect Raises USD40 Million in Public Offering of Shares and Warrants 19

ContraFect to Raise Up to USD4.9 Million in Public Offering of Shares 21

ContraFect Raises Funds through Public Offering of Shares and Warrants 22

ContraFect Raises USD35 Million in Public Offering of Shares 23

ContraFect Raises USD20 Million in Private Placement Shares and Warrants 24

ContraFect Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD41 Million 25

ContraFect Corp, Key Competitors 27

ContraFect Corp, Key Employees 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ContraFect Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.